Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) were down 2.4% during mid-day trading on Thursday. The stock traded as low as $1.95 and last traded at $2.02. 84,364 shares changed hands during mid-day trading, an increase of 438% from the average daily volume of 15,685 shares. The stock had previously closed at $2.07.
AlloVir Stock Down 6.0%
The stock has a market cap of $9.43 million, a PE ratio of -0.09 and a beta of 0.63. The business has a 50 day moving average price of $3.20 and a 200 day moving average price of $4.25.
About AlloVir
AlloVir, Inc was a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, virus-specific T-cell therapies for patients whose immune systems are compromised and who are unable to effectively fight viral infections. Its approach was designed to restore or enhance antiviral immunity without requiring the patient to generate an effective immune response independently.
The company’s pipeline included posoleucel, also known as ALVR105, an investigational multi-virus-specific T-cell therapy targeting infections caused by adenovirus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, BK virus and JC virus.
Read More
- Five stocks we like better than AlloVir
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
